Us Induced Pluripotent Stem Cells Market Analysis

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW OF U.S. INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET

1.4 CURRENCY AND PRICING

1.5 LIMITATIONS

1.6 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 MARKETS COVERED

2.2 YEARS CONSIDERED FOR THE STUDY

2.3 DBMR TRIPOD DATA VALIDATION MODEL

2.4 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS

2.5 DBMR MARKET POSITION GRID

2.6 MULTIVARIATE MODELLING

2.7 TYPE LIFELINE CURVE

2.8 MARKET END USER COVERAGE GRID

2.9 SECONDARY SOURCES

2.1 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

4.1 PESTEL ANALYSIS

4.2 PORTER’S FIVE FORCES

5 MARKET OVERVIEW

5.1 DRIVERS

5.1.1 TECHNOLOGICAL ADVANCEMENT IN REGENERATIVE MEDICINE

5.1.2 EXPANDING APPLICATIONS IN DRUGS DISCOVERY

5.2 RESTRAINTS

5.2.1 SAFETY CONCERNS AND TECHNICAL DIFFICULTIES

5.2.2 COMPETITION AND INTELLECTUAL PROPERTY ISSUES

5.3 OPPORTUNITIES

5.3.1 INCREASING INTEREST OF PERSONALIZED MEDICINE

5.3.2 INCREASING ADOPTION OF STEM CELL THERAPY

5.4 CHALLENGE

5.4.1 HIGH COST ASSOCIATED WITH STEM CELL THERAPIES

6 U.S. INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY MODEL TYPE

6.1 OVERVIEW

6.2 ECM PATTERNED PAA/PDMS SUBSTRATES

6.3 MICROGROOVE PDMS SUBSTRATES

6.4 STRAINED MEMBRANES

6.5 3D SACFFOLDS

6.6 FREE-FLOATING HYDROGEL CONTRUCTS

6.7 EHTS

7 U.S. INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY MATERIAL

7.1 OVERVIEW

7.2 NATURAL HYDROGEL- BASED CARDIAC MODELS

7.3 SYNTHETICS FIBROUS CARDIAC MODELS

7.3.1 POLYGLYCOLIC ACID (PGA)

7.3.2 POLY E-CAPROLACTONE (PCL)

7.3.3 POLYURETHANE

7.3.4 POLYLACTIC ACID (PLA)

7.3.5 OTHERS

8 U.S. INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY CELL SOURCE

8.1 OVERVIEW

8.2 SKIN CELLS

8.2.1 FIBROBLAST

8.2.2 KERATINOCYTES

8.2.3 MELANOCYTES

8.2.4 NEURAL STEM CELLS

8.2.5 ADIPOSE DERIVE STEM CELLS

8.2.6 OTHERS

8.3 BLOOD CELLS

8.3.1 PERIPHERAL BLOOD MONOCLEAR CELLS

8.3.2 CORD BLOOD ENDOTHELIAL CELLS

8.3.3 CORD BLOOD STEM CELLS

8.3.4 OTHERS

9 U.S. INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY DIMENSIONAL TYPE

9.1 OVERVIEW

9.2 3D

9.3 SKIN CELLS

9.3.1 FIBROBLAST

9.3.2 KERATINOCYTES

9.3.3 MELANOCYTES

9.3.4 NEURAL STEM CELLS

9.3.5 ADIPOSE DERIVE STEM CELLS

9.3.6 OTHERS

9.4 BLOOD CELLS

9.4.1 PERIPHERAL BLOOD MONOCLEAR CELLS

9.4.2 CORD BLOOD ENDOTHELIAL CELLS

9.4.3 CORD BLOOD STEM CELLS

9.4.4 OTHERS

9.5 2D

9.5.1 SKIN CELLS

9.5.1.1 FIBROBLAST

9.5.1.2 KERATINOCYTES

9.5.1.3 MELANOCYTES

9.5.1.4 NEURAL STEM CELLS

9.5.1.5 ADIPOSE DERIVE STEM CELLS

9.5.1.6 OTHERS

9.5.2 BLOOD CELLS

9.5.2.1 PERIPHERAL BLOOD MONOCLEAR CELLS

9.5.2.2 CORD BLOOD ENDOTHELIAL CELLS

9.5.2.3 CORD BLOOD STEM CELLS

9.5.2.4 OTHERS

10 U.S. INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY APPLICATION

10.1 OVERVIEW

10.2 PRODUCTION OF NEW CARDIAC TISSUE TO REPLACE TISSUES DESTROYED BY INFRACTION OR OTHER DISEASES

10.3 HEART FAILURE

10.4 ISCHEMIC HEART DISEASE

10.5 ARRYTHMIA

10.6 CARDIOMYOPATHIES

10.7 VALVULAR HEART DISEASE

10.8 HEART DISEASE SCREENING

10.9 OTHERS

11 U.S. INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY END USE

11.1 OVERVIEW

11.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES

11.3 ACADEMIC AND GOVERNMENT RESEARCH INSTITUTES

11.4 CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATIONS

11.5 OTHERS

12 U.S. INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY DISTRIBUTION CHANNEL

12.1 OVERVIEW

12.2 DIRECT TENDER

12.3 RETAIL SALES

13 U.S. INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET: COMPANY LANDSCAPE

13.1 COMPANY SHARE ANALYSIS: U.S.

14 SWOT ANALYSIS

15 COMPANY PROFILE

15.1 CORNING INCRPORATED

15.1.1 COMPANY SNAPSHOT

15.1.2 REVENUE ANALYSIS

15.1.3 PRODUCT PORTFOLIO

15.1.4 RECENT DEVELOPMENT

15.2 LONZA

15.2.1 COMPANY SNAPSHOT

15.2.2 REVENUE ANALYSIS

15.2.3 PRODUCT PORTFOLIO

15.2.4 RECENT DEVELOPMENT

15.3 MIMETAS

15.3.1 COMPANY SNAPSHOT

15.3.2 PRODUCT PORTFOLIO

15.3.3 RECENT DEVELOPMENT

15.4 REPROCELL INC.

15.4.1 COMPANY SNAPSHOT

15.4.2 PRODUCT PORTFOLIO

15.4.3 RECENT DEVELOPMENT

15.5 CN BIO INNOVATIONS

15.5.1 COMPANY SNAPSHOT

15.5.2 PRODUCT PORTFOLIO

15.5.3 RECENT DEVELOPMENT

15.6 AXOL BIOSCIENCE LTD.

15.6.1 COMPANY SNAPSHOT

15.6.2 PRODUCT PORTFOLIO

15.6.3 RECENT DEVELOPMENT

15.7 3D BIOTEK LLC.

15.7.1 COMPANY SNAPSHOT

15.7.2 PRODUCT PORTFOLIO

15.7.3 RECENT DEVELOPMENT

16 QUESTIONNAIRE

17 RELATED REPORTS